Catheter-Based Renal Denervation for Hypertension

  • Raymond R. TownsendEmail author
  • Paul A. Sobotka
Hypertension and the Kidney (RM Carey, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hypertension and the Kidney


Purpose of Review

This review was undertaken to update readers on the field of therapeutic renal denervation for hypertension during the 2016 through 2018 period.

Recent Findings

After the failure of Symplicity HTN-3 to meet its top line objective, intense scrutiny revealed several possible concerns addressed by the newer investigations into the area of renal denervation. These included better device technology, more intense subject monitoring for off-protocol antihypertensive drug usage, and deeper penetration into the renal vasculature by the interventionist.


Whether untreated by medication for hypertension or on antihypertensive medication, renal denervation shows a clear, though moderate, blood pressure reduction. The failure of roughly one out of three patients with hypertension to respond to denervation procedures argues that there is room for improvement in choosing the optimal patient for this approach to hypertension management.


Renal denervation Hypertension Radiofrequency ablation Ultrasound ablation Alcohol ablation 


Compliance with Ethical Standards

Conflict of Interest

Dr. Townsend reports personal fees from Medtronic and Rox Medical, outside the submitted work. Dr. Sobotka is Executive Consultant to Rox Medical.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Krum H, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. First human series of patients treated for drug resistant hypertension using radiofrequency renal ablation. CrossRefPubMedGoogle Scholar
  2. 2.
    Esler MD, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Kandzari DE, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. ClinCardiol. 2012;35(9):528–35.Google Scholar
  4. 4.
    Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.CrossRefPubMedGoogle Scholar
  5. 5.
    Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Kandzari DE, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. In: Eur.Heart J, vol. 36; 2014. p. 219–27.Google Scholar
  7. 7.
    Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Fischell TA, Ebner A, Gallo S, Ikeno F, Minarsch L, Vega F, et al. Transcatheter alcohol-mediated perivascular renal denervation with the Peregrine system: first-in-human experience. JACC Cardiovasc Interv. 2016;9(6):589–98.CrossRefPubMedGoogle Scholar
  9. 9.
    Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    •• Jung O, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74. Important study which highlighted the substantial prevalence of drug-non-adherence in resistant hypertebnsion. CrossRefPubMedGoogle Scholar
  11. 11.
    Florczak E, et al. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn. 2015;125(1–2):65–72.PubMedGoogle Scholar
  12. 12.
    Patel P, Gupta PKC, White CMJ, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Flack JM, et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9:769–79.CrossRefPubMedGoogle Scholar
  15. 15.
    •• Mahfoud F, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the global SYMPLICITY registry. Eur Heart J. 2017;38(2):93–100. This registry will be an important source of long-term efficacy and saftery of renal denervation. PubMedGoogle Scholar
  16. 16.
    • Sata Y, et al. Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation. J Hypertens. 2018;36(6):1414–22. Given the difficulty predicting responses in RDN studies like this are going to become inreasingly important as subject selection is streamlined. CrossRefPubMedGoogle Scholar
  17. 17.
    •• Osborn JW, Foss JD. Renal nerves and long-term control of arterial pressure. Compr Physiol. 2017;7(2):263–320. Well-written and comprehensive review or renal nerve anatomy and role in renal function. CrossRefPubMedGoogle Scholar
  18. 18.
    Petrov I, Tasheva I, Garvanski I, Stankov Z, Simova I. Comparison of standard renal denervation procedure versus novel distal and branch vessel ablation with brachial arterial access. In: Cardiovasc Revasc Med; 2018. Scholar
  19. 19.
    Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol. 2015;66(16):1766–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Fudim M, Sobotka AA, Yin YH, Wang JW, Levin H, Esler M, et al. Selective vs. global renal denervation: a case for less is more. Curr Hypertens Rep. 2018;20(5):37.CrossRefPubMedGoogle Scholar
  21. 21.
    Tsioufis C, Dimitriadis K, Tsioufis P, Patras R, Papadoliopoulou M, Petropoulou Z, et al. ConfidenHT system for diagnostic mapping of renal nerves. Curr Hypertens Rep. 2018;20(6):49.CrossRefPubMedGoogle Scholar
  22. 22.
    DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75–197.CrossRefPubMedGoogle Scholar
  23. 23.
    Kopp UC. Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Integr Comp Physiol. 2015;308(2):R79–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Kopp UC, et al. Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1561–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Ueda H, Uchida Y, Kamisaka K. Mechanism of the reflex depressor effect by the kidney in dog. Jpn Heart J. 1967;8(6):597–606.CrossRefPubMedGoogle Scholar
  26. 26.
    Handa RK, Johns EJ. Interaction of the renin–angiotensin system and the renal nerves in the regulation of rat kidney function. J Physiol. 1985;369:311–21.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633–41.CrossRefPubMedGoogle Scholar
  28. 28.
    Fudim M, Hernandez AF, Felker GM. Role of volume redistribution in the congestion of heart failure. J Am Heart Assoc. 2017;6(8):e006817.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lambert T, Nahler A, Reiter C, Schwarz S, Gammer V, Blessberger H, et al. Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension. Am J Cardiol. 2015;115(11):1545–8.CrossRefPubMedGoogle Scholar
  30. 30.
    •• Pappaccogli, M., et al., Effectiveness of renal denervation in resistant hypertension: a meta-analysis of 11 controlled studies. High Blood Press Cardiovasc Prev, 2018. Accessed 11 May 2018. This analysis was published before more recent studies. It basically finds little benefit in RDN as done in the period up to about 2016 . CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Perelman School of Medicine, Renal, Electrolyte and Hypertension DivisionUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.The Ohio StateColumbusUSA
  3. 3.Chief Medical OfficerRox Medical, Inc.San ClementeUSA

Personalised recommendations